Literature DB >> 1792636

Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler.

O Selroos1, M Halme.   

Abstract

BACKGROUND: High doses of inhaled corticosteroids are absorbed systemically and may cause long term side effects. As rinsing the mouth out after use and inhaling through a spacing device may reduce systemic absorption this has been further investigated.
METHODS: Three crossover studies were carried out to assess the effect of budesonide given by dry powder inhaler (Turbuhaler) with and without mouth rinsing and beclomethasone dipropionate given by metered dose inhaler with or without a spacing device (Volumatic) on serum cortisol concentrations and urinary cortisol excretion in patients with asthma taking an inhaled corticosteroid. Each treatment period was two weeks with in a two week washout period. Serum cortisol concentrations at 0800 hours on day 14 and the 24 hour urinary excretion of cortisol were measured. In study 1 24 patients taking beclomethasone dipropionate 500 micrograms twice a day inhaled with (n = 10) or without (n = 14) a Volumatic spacing device were switched to a budesonide dry powder inhaler, 600 micrograms to be taken twice a day without mouth rinsing. In study 2 10 patients took budesonide 800 micrograms twice a day with and without mouth rinsing and without swallowing the rinsing water. In study 3 17 patients took budesonide 800 micrograms twice daily with mouth rinsing and beclomethasone dipropionate 500 micrograms twice daily with the spacing device and mouth rinsing.
RESULTS: In study 1 no difference was seen between budesonide without mouth rinsing and beclomethasone dipropionate without a spacer: beclomethasone with spacer caused less suppression of cortisol (mean (SD) serum cortisol concentration: beclomethasone and spacer 487(148), budesonide 368(145) nmol/l). In study 2 mouth rinsing caused less suppression of morning serum cortisol concentrations (rinsing 440(63), no rinsing 375(56) nmol/1). In study 3 there was no difference in serum or urinary cortisol concentrations between twice daily beclomethasone dipropionate 500 micrograms inhaled by Volumatic spacer or budesonide by Turbuhaler 800 micrograms twice daily, both with mouth rinsing. Individual serum cortisol values were within the normal range in all patients except one in study 1.
CONCLUSION: Systemic absorption of a corticosteroid inhaled from a metered dose inhaler is reduced by using a spacing device and that from a dry powder inhaler by mouth rinsing.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1792636      PMCID: PMC463494          DOI: 10.1136/thx.46.12.891

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  11 in total

1.  Morning serum cortisol concentrations after 2 mg inhaled beclomethasone dipropionate in normal subjects: effect of a 750 ml spacing device.

Authors:  M Farrer; A J Francis; S J Pearce
Journal:  Thorax       Date:  1990-10       Impact factor: 9.139

2.  Aerosol beclomethasone dipropionate: a dose-response study in chronic bronchial asthma.

Authors:  J Gaddie; G R Petrie; I W Reid; C Skinner; D J Sinclair; K N Palmer
Journal:  Lancet       Date:  1973-08-11       Impact factor: 79.321

3.  The effect of oral and inhaled beclomethasone dipropionate on adrenal function.

Authors:  D M Harris; L E Martin; C Harrison; D Jack
Journal:  Clin Allergy       Date:  1973-09

4.  Beclomethasone dipropionate by inhalation in the treatment of airways obstruction.

Authors:  Y F Choo-Kang; E J Cooper; A E Tribe; I W Grant
Journal:  Br J Dis Chest       Date:  1972-04

5.  Improvement of pressurised aerosol deposition with Nebuhaler spacer device.

Authors:  S P Newman; A B Millar; T R Lennard-Jones; F Morén; S W Clarke
Journal:  Thorax       Date:  1984-12       Impact factor: 9.139

6.  Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids?

Authors:  P H Brown; G Blundell; A P Greening; G K Crompton
Journal:  Thorax       Date:  1990-10       Impact factor: 9.139

7.  Clinical use of spacer systems for corticosteroid inhalation therapy: a preliminary analysis.

Authors:  J H Toogood; B Jennings; J Baskerville; S A Johansson
Journal:  Eur J Respir Dis Suppl       Date:  1982

8.  Turbuhaler: a new powder inhaler for administration of drugs to the airways.

Authors:  K Wetterlin
Journal:  Pharm Res       Date:  1988-08       Impact factor: 4.200

9.  Decreased adreno-cortical suppression utilizing the Nebuhaler for inhalation of steroid aerosols.

Authors:  P Prahl; T Jensen
Journal:  Clin Allergy       Date:  1987-09

10.  Effects of long term inhaled high dose beclomethasone dipropionate on adrenal function.

Authors:  M J Smith; M E Hodson
Journal:  Thorax       Date:  1983-09       Impact factor: 9.139

View more
  30 in total

Review 1.  Management of asthma in adults: current therapy and future directions.

Authors:  R H Green; C E Brightling; I D Pavord; A J Wardlaw
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

2.  Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device.

Authors:  D M Newnham; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

Review 3.  Recent advances in asthma.

Authors:  P J Barnes; T H Lee
Journal:  Postgrad Med J       Date:  1992-12       Impact factor: 2.401

Review 4.  Deposition and effects of inhaled corticosteroids.

Authors:  Stephen P Newman
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  Overcoming gaps in the management of asthma in older patients: new insights.

Authors:  Pranoy Barua; M Sinead O'Mahony
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  Delivering inhaled corticosteroids to patients.

Authors:  C O'Callaghan; P Barry
Journal:  BMJ       Date:  1999-02-13

Review 7.  Optimizing inhaled drug delivery in patients with asthma.

Authors:  C Jackson; B Lipworth
Journal:  Br J Gen Pract       Date:  1995-12       Impact factor: 5.386

Review 8.  Treatment of childhood asthma: how do the available options compare?

Authors:  David Coghlan; Colin Powell
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function.

Authors:  P H Brown; A P Greening; G K Crompton
Journal:  Thorax       Date:  1993-03       Impact factor: 9.139

Review 10.  Pharmacokinetic optimisation of inhaled steroid therapy in asthma.

Authors:  I Pavord; A Knox
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.